Stoke Therapeutics: Vulnerable To Profit Taking

2025-08-27 10:06:16 ET

Shares of RNA medicine concern Stoke Therapeutics, Inc. ( STOK ) have more than tripled off their recent lows in early April. Stoke's antisense oligonucleotide zorevunersen has demonstrated significant seizure reduction in Dravet syndrome patients to date, prompting a Breakthrough Therapy designation from the FDA. With an operating runway into mid-2028, a recently inked commercialization deal with Biogen for zorevunersen ex-North America, but no new data until YE27, this clinical-stage biotech name merited a deeper dive. An analysis/recommendation follows below....

Read the full article on Seeking Alpha

For further details see: